Aldeyra Therapeutics Revenue, Profits - ALDX Quarterly Income Statement

Add to My Stocks
$9.1 $0.6 (7.06%) ALDX stock closing price Sep 21, 2018 (Closing)

ALDX stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Aldeyra Therapeutics stock price. An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. Like any other income statement, the ALDX income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a QoQ revenue decline of 0 when compared to the same period in the past. Along with Aldeyra Therapeutics assets and Aldeyra Therapeutics free cash flow, Aldeyra Therapeutics profits as shown in profit and loss statement give key insights about the business. The net profit for 2018 Q2 is $-9.05M and the 2018 Q2 revenue is $-.

View and download details of revenue and profits for Aldeyra Therapeutics for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Aldeyra Therapeutics Revenues or Net Sales
Cost Of Goods Sold (COGS)----------
Aldeyra Therapeutics Gross Profit
Research & Development Expense6.79M6.6M5.57M3.53M3.84M3.36M3.46M3.37M2.83M3.51M
Selling General & Admin Expense2.37M1.89M1.51M1.47M1.48M1.72M1.22M1.39M1.46M1.45M
Income Before Depreciation Depletion Amortization-9.16M-8.49M-7.05M-5.01M-5.33M-5.09M-4.67M-4.77M-4.29M-4.96M
Depreciation Depletion Amortization----------
Non Operating Income----------
Interest Expense----------
Aldeyra Therapeutics Pretax Income
Provision for Income Taxes----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-9.05M-8.4M-6.96M-4.99M-5.31M-5.09M-4.65M-4.78M-4.3M-4.97M
Extraordinary Items & Discontinued Operations----------
Aldeyra Therapeutics Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS19.76M19.37M18.97M15.58M15.14M13.8M12.8M12.48M10.62M9.71M
Average Shares used to compute Basic EPS19.76M19.37M18.97M15.58M15.14M13.8M12.8M12.48M10.62M9.71M
Income Before Nonrecurring Items-9.05M-8.4M-6.96M-4.99M-5.31M-5.09M-4.65M-4.78M-4.3M-4.97M
Income from Nonrecurring Items----------
Aldeyra Therapeutics Earnings Per Share Basic Net
Aldeyra Therapeutics Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.46-0.43-0.37-0.32-0.35-0.37-0.36-0.38-0.41-0.51
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Before investing one should read a report on Aldeyra Therapeutics stock analysis. It helps to look at the following income statement items:

  • Topline: A growing topline, as seen from the Aldeyra Therapeutics revenue chart, as isn't the case with Aldeyra Therapeutics indicates a sagging business. One needs to compare the QoQ topline or sales growth of ALDX stock with its peers like TTPH stock and NATR stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-9.05M for Aldeyra Therapeutics for 2018 Q2. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the ALDX income statement, one can check the Aldeyra Therapeutics historical stock prices to check how the price has moved with time.

Aldeyra Therapeutics Income Statement - Key Financial Ratios